International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.
International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.
Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.
Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.
International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.
Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.
Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.
Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.
An International Open Access Journal Devoted to General Medicine.
Oncol Rep 44: [Related article:] 2725–2734, 2020; DOI: 10.3892/or.2020.7789
Subsequently to the publication of the above paper, an interested reader drew to the authors' attention that the western blot Hsp90α bands in Fig. 1A were strikingly similar to data featured in two other papers written by the same research group; in Fig. 3A of reference 20 (by Qilin Wang et al, in the journal Cancer Cell International, published in 2012), and Fig. 8A in reference 43 (by Qilin Wang and Xiangguo Liu, also in the journal Cancer Cell International, published in 2020). The authors explained that they performed the Hsp90α knockdown experiments and western blot assays using duplicate membranes from the same experiments, although these were published separately in the three papers. The Hsp90α data were intentionally shared among the papers in order to show the same knockdown efficiency. Secondly, the microscopic image showing 1.0 µM Tanespimycin treatment in Fig. 2C of the abovementioned article had also apparently been included in Fig. 5B in a paper by Qilin Wang and Xiangguo Liu published in 2020, also in the journal Cancer Cell International. In that case, the authors re-examined their original data, and realized that the data in question in Fig. 2C had been inadvertently copied during editing.
The authors proposed providing alternative data for Fig. 1A from other independent Hsp90α and Hsp90β knockdown experiments, respectively, and the revised version of Fig. 1 is shown on the next page. The revised version of Fig. 2, now showing all the correct data in Fig. 2C, is shown on the third page. The authors regret the errors that were made during the compilation of the original figures, and are grateful to the editor of Oncology Reports for allowing them the opportunity to publish this Corrigendum. Note that these errors did not have a significant impact on the conclusions reached in this study. All the authors agree with the publication of this corrigendum; furthermore, they apologize to the readership for any inconvenience caused.